<DOC>
	<DOCNO>NCT02550249</DOCNO>
	<brief_summary>Neoadjuvant nivolumab administer patient primary recurrent glioblastoma multiforme require surgery . Nivolumab continue follow surgery .</brief_summary>
	<brief_title>Neoadjuvant Nivolumab Glioblastoma</brief_title>
	<detailed_description>Neoadjuvant nivolumab administer patient primary recurrent glioblastoma multiforme require surgery . Nivolumab continue follow surgery toxicity progression .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Written inform consent . Patients must willing able comply schedule visit , treatment schedule , laboratory testing requirement study . Patients GBM candidate primary salvage resection surgery , accord follow criterion : Patients may receive previous treatment GBM . There limit previous treatment line , long inclusion criterion meet . Patients surgery safely delay minimum period 2 week follow administration first dose nivolumab , opinion investigator . Eastern Cancer Oncology Group ( ECOG ) performance status 01 . Patients ECOG &gt; 1 due neurological symptom consider reversible follow surgery , accord investigator´s criterion eligible Life expectancy &gt; 12 week . Adequate organ function define : 1 . Bone Marrow Reserve : white blood cell ( WBC ) : ≥2000/ mm3 absolute neutrophil count ( ANC ) ≥1500x 109/L ; platelet count ≥100000/ mm3 100 x 109/L ; hemoglobin ≥9.0 g/dL ) . 2 . Hepatic : bilirubin &lt; 1.5 time upper limit normality ( ULN ) , AST ALT &lt; 3.0 × ULN ( BR &lt; 3 x ULN patient Gilbert´s Syndrome ) . 3 . Renal : creatinine &lt; 1.5 x ULN estimate creatinine clearance &gt; 40 ml/min , use CockcroftGault formula . Presence extracranial disease . Any serious uncontrolled medical disorder , opinion investigator , may increase risk associate study participation study drug administration , impair ability subject receive plan therapy ( include brain surgery ) , interfere interpretation study result . Subjects active , know suspected autoimmune disease . Subjects vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit enroll . Previous treatment PD1 , PDL1 CTLA4 target therapy Treatment anticancer drug radiation therapy within last 14 day . A short interval approve principal investigator , deem appropriate . Patients exclude condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) , exception control cerebral edema , immunosuppressive medication within 14 day study drug administration . Inhaled topical steroid adrenal replacement dos &gt; 10 mg daily prednisone equivalent permit absence active autoimmune disease . Pregnant breastfeeding patient . Known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . Routine testing require . Positive test hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( HCV RNA ) indicate active chronic infection . History allergy study drug component severe hypersensitivity reaction monoclonal antibody . Prisoners subject involuntarily incarcerate compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness . Subjects unable ( due existent medical condition , e.g , pacemaker implantable cardioverter defibrillator device ) unwilling head contrast enhance MRI and/or CT scan brain . Concomitant prior malignancy , opinion investigator contraindicate GBM surgery interfere result study , opinion investigator . Known drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>